Oncology Hematology Care, Cincinnati, OH 45242, USA.
McKesson Life Sciences, The Woodlands, TX 77380, USA.
Future Oncol. 2021 Jul;17(19):2439-2448. doi: 10.2217/fon-2021-0047. Epub 2021 Mar 26.
To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Retrospective database analysis. In all, 469 patients received first-line systemic anticancer therapy (SACT) at community centers. Median follow-up from diagnosis was 11.6 months. Pemetrexed + platinum was the most common first-line SACT; similar proportions of patients received cisplatin or carboplatin with pemetrexed. Only a small proportion of patients received second- and third-line therapies. Median overall survival for first-line SACT was 12.0 months (95% CI: 10.7-14.2). Results were similar with pemetrexed + cisplatin and pemetrexed + carboplatin. Median overall survival with second-line SACT was 6.4 months (95% CI: 5.1-7.6). There is a need for more effective SACTs for advanced malignant pleural mesothelioma.
评估晚期恶性胸膜间皮瘤患者的真实世界治疗模式和结局。回顾性数据库分析。共有 469 例患者在社区中心接受一线系统抗癌治疗（SACT）。从诊断到中位随访时间为 11.6 个月。培美曲塞+铂类是最常见的一线 SACT；接受顺铂或卡铂联合培美曲塞治疗的患者比例相似。只有一小部分患者接受二线和三线治疗。一线 SACT 的中位总生存期为 12.0 个月（95%CI：10.7-14.2）。培美曲塞+顺铂和培美曲塞+卡铂的结果相似。二线 SACT 的中位总生存期为 6.4 个月（95%CI：5.1-7.6）。对于晚期恶性胸膜间皮瘤，需要更有效的 SACT。
